CACaption Management, LLC
Institutional investor · Portfolio as of Q1 2026
Top Holdings1,484 positions
META PLATFORMS INC | 2M | $1.1B | 6.7% | — | — | — | New — |
UNITED THERAPEUTICS CORP DEL | 667,200 | $395.6M | 2.3% | — | — | — | Increased — |
CARVANA CO | 1.1M | $357.6M | 2.1% | — | — | — | Increased — |
WARNER BROS DISCOVERY INC | 11.9M | $327.2M | 1.9% | — | — | — | Increased — |
ELECTRONIC ARTS INC | 1.4M | $277M | 1.6% | — | — | — | New — |
NVIDIA CORPORATION | 1.6M | $274.7M | 1.6% | — | — | — | Increased — |
NVIDIA CORPORATION | 1.5M | $262.9M | 1.5% | $183.31 | -5.08% | 3 qtrssince 2025-Q3 | Increased 61 |
UNITED THERAPEUTICS CORP DEL | 410,000 | $243.1M | 1.4% | — | — | — | Increased — |
BLUE OWL CAPITAL INC | 23M | $209.5M | 1.2% | — | — | — | Increased — |
AMAZON COM INC | 1M | $208.3M | 1.2% | — | — | — | New — |
CARVANA CO | 579,500 | $182.2M | 1.1% | — | — | — | Decreased — |
NVIDIA CORPORATION | 896,000 | $156.3M | 0.9% | — | — | — | Increased — |
WARNER BROS DISCOVERY INC | 5.4M | $149M | 0.9% | — | — | — | Increased — |
BLUE OWL CAPITAL INC | 15.1M | $138M | 0.8% | $9.31 | -5.97% | 3 qtrssince 2025-Q3 | Increased 69 |
TAKE-TWO INTERACTIVE SOFTWAR | 661,300 | $130.6M | 0.8% | — | — | — | Increased — |
MICROSOFT CORP | 350,000 | $129.6M | 0.8% | — | — | — | Increased — |
ISHARES TR | 1.5M | $123.1M | 0.7% | — | — | — | New — |
LUMENTUM HLDGS INC | 175,000 | $123M | 0.7% | — | — | — | Increased — |
REVOLUTION MEDICINES INC | 1.2M | $119.3M | 0.7% | — | — | — | New — |
SPDR SERIES TRUST | 894,100 | $114.2M | 0.7% | — | — | — | Increased — |
Caption Management, LLC manages $17.1B across 1484 positions as of Q1 2026. Top holdings: META calls (6.7%), UTHR calls (2.3%), CVNA puts (2.1%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1/5.0.
Active quarter - 257 new positions, 263 exits, 120 increased. Top move: OWL (INCREASED, conviction 69). Portfolio: $17.1B across 1484 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR